Keith A. Cengel

Keith A. Cengel

Auto-generated profile, based on publicly available information

Keith A. Cengel

Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2011 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
PDF file
PAPatrizia Agostinis
Patrizia Agostinis
Kristian BergKristian Berg
Kristian Berg
KCKeith A. Cengel
Keith A. Cengel
TFThomas H. Foster
Thomas H. Foster
Albert GirottiAlbert Girotti
Albert Girotti
JGJakub Golab
Jakub Golab
CA: A Cancer Journal for Clinicians publishes information about the prevention, early detection, and treatment of cancer, as well as nutrition, palliative care, survivorship, and additional topics of interest related to cancer care.

1 February 2020 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
EDEric S. Diffenderfer
Eric S. Diffenderfer
IVIoannis I. Verginadis
Ioannis I. Verginadis
MKMichele M. Kim
Michele M. Kim
KSKhayrullo Shoniyozov
Khayrullo Shoniyozov
AVAnastasia Velalopoulou
Anastasia Velalopoulou
KCKeith A. Cengel
Keith A. Cengel
Recent studies suggest that ultrahigh-dose-rate, "FLASH," electron radiation therapy (RT) decreases normal tissue damage while maintaining tumor response compared with conventional dose rate RT. Here, we describe a novel RT apparatus that delivers FLASH proton RT (PRT) using double scattered protons with computed tomography guidance and provide the first report of proton FLASH RT-mediated normal tissue radioprotection. Absolute dose was measured at multiple depths in solid water and validated against an absolute integral charge measurement using a Faraday cup. Real-time dose rate was obtained using a NaI detector to measure prompt gamma rays. The effect of FLASH versus standard dose rate PRT on tumors and normal tissues was measured using pancreatic flank tumors (MH641905) derived from the KPC autochthonous PanCa model in syngeneic C57BL/6J mice with analysis of fibrosis and stem cell repopulation in small intestine after abdominal irradiation. The double scattering and collimation apparatus was dosimetrically validated with dose rates of 78 ± 9 Gy per second and 0.9 ± 0.08 Gy per second for the FLASH and standard PRT. Whole abdominal FLASH PRT at 15 Gy significantly reduced the loss of proliferating cells in intestinal crypts compared with standard PRT. Studies with local intestinal irradiation at 18 Gy revealed a reduction to near baseline levels of intestinal fibrosis for FLASH-PRT compared with standard PRT. Despite this difference, FLASH-PRT did not demonstrate tumor radioprotection in MH641905 pancreatic cancer flank tumors after 12 or 18 Gy irradiation. We have designed and dosimetrically validated a FLASH-PRT system with accurate control of beam flux on a millisecond time scale and online monitoring of the integral and dose delivery time structure. Using this system, we found that FLASH-PRT decreases acute cell loss and late fibrosis after whole-abdomen and focal intestinal RT, whereas tumor growth inhibition is preserved between the 2 modalities.

23 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MKMichele Kim
Michele Kim
IVIoannis I. Verginadis
Ioannis I. Verginadis
DGDenisa Goia
Denisa Goia
AHAllison Haertter
Allison Haertter
KSKhayrullo Shoniyozov
Khayrullo Shoniyozov
EDEric Diffenderfer
Eric Diffenderfer
Ultra-high dose rate FLASH proton radiotherapy (F-PRT) has been shown to reduce normal tissue toxicity compared to standard dose rate proton radiotherapy (S-PRT) in experiments using the entrance portion of the proton depth dose profile, while proton therapy uses a spread-out Bragg peak (SOBP) with unknown effects on FLASH toxicity sparing. To investigate, the biological effects of F-PRT using an SOBP and the entrance region were compared to S-PRT in mouse intestine. In this study, 8–10-week-old C57BL/6J mice underwent 15 Gy (absorbed dose) whole abdomen irradiation in four groups: (1) SOBP F-PRT, (2) SOBP S-PRT, (3) entrance F-PRT, and (4) entrance S-PRT. Mice were injected with EdU 3.5 days after irradiation, and jejunum segments were harvested and preserved. EdU-positive proliferating cells and regenerated intestinal crypts were quantified. The SOBP had a modulation (width) of 2.5 cm from the proximal to distal 90%. Dose rates with a SOBP for F-PRT or S-PRT were 108.2 ± 8.3 Gy/s or 0.82 ± 0.14 Gy/s, respectively. In the entrance region, dose rates were 107.1 ± 15.2 Gy/s and 0.83 ± 0.19 Gy/s, respectively. Both entrance and SOBP F-PRT preserved a significantly higher number of EdU + /crypt cells and percentage of regenerated crypts compared to S-PRT. Moreover, tumor growth studies showed no difference between SOBP and entrance for either of the treatment modalities.

23 June 2020 in Photochemistry and Photobiology
Verified
Journal Article
Closed access
PDF file
GCGwendolyn M. Cramer
Gwendolyn M. Cramer
EMEdmund K. Moon
Edmund K. Moon
KCKeith A. Cengel
Keith A. Cengel
Theresa M. BuschTheresa M. Busch
Theresa M. Busch

7 May 2012 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
PDF file
LFL. Fishbein
L. Fishbein
LBL. Bonner
L. Bonner
DTD. A. Torigian
D. A. Torigian
KNKatherine Nathanson
Katherine Nathanson
DCD. L. Cohen
D. L. Cohen
KCK. A. Cengel
K. A. Cengel
In patients with malignant pheochromocytoma and paraganglioma, 131I-MIBG radiotherapy can achieve an objective response rate of 30–50% with the dose limiting toxicity being hematologic. Patients with disseminated disease, who also have a few index bulky or symptomatic lesions, may benefit from the addition of targeted external beam radiotherapy alone or in combination with systemic 131I-MIBG. The records of patients with malignant paraganglioma who were treated with external beam radiotherapy at the University of Pennsylvania from February 1973 to February 2011 were reviewed in an institutional review board approved retrospective study. Of the 17 patients with tumors in the thorax, abdomen, or pelvis, 76% had local control or clinically significant symptomatic relief for at least 1 year or until death. As expected, the predominant toxicity was due to irradiation of tumor-adjacent normal tissues without clinically significant hematologic toxicity. Due to widespread systemic metastases with areas of bulky, symptomatic tumor, 5 of the 17 patients were treated with sequential 131I-MIBG (2 mCi/kg per treatment) and external beam radiotherapy to 9 sites. In these patients, all areas that were irradiated with external beam radiotherapy showed durable objective response despite all patients eventually experiencing out-of-field systemic progression requiring other treatment. Four of these patients remain alive with excellent performance status 16, 18, 23, and 24 months after external beam radiotherapy. External beam radiotherapy can be highly effective in local management of malignant paraganglioma and can be used in conjunction with 131I-MIBG due to nonoverlapping toxicities with excellent control of locally bulky tumors.

1 August 2013 in Bone
Verified
Journal Article
Closed access
ACAbhishek Chandra
Abhishek Chandra
SLShenghui Lan
Shenghui Lan
JZJi Zhu
Ji Zhu
TLTiao Lin
Tiao Lin
XZXianrong Zhang
Xianrong Zhang
LQLing Qin
Ling Qin